Dignitana AB, a leader in medical scalp cooling technology, manufactures the DigniCap system to reduce hair loss during chemotherapy. The company received FDA clearance in December 2015 and has signed contracts with ten U.S. cancer centers. Dignitana is listed on NASDAQ First North and aims to expand in the U.S. market. The business model includes leasing the system and receiving payment per treatment. The company holds patents on sensors and coolant circuits. Financials for 2015 show a focus on FDA approval and organizational development, impacting sales.
documents/EFTA01114097.pdf
{}